Back to trial
Eligibility Pre-Screening
Long term impact of RAS inhibition on cardio-renal outcomes: a comparative trial of angiotensin converting enzyme inhibitors, angiotensin receptor blockers or combined therapy with both agents in patients with one or more cardiovascular risk factors and microalbuminuria, diabetic or not diabetic.
This is a simplified pre-screening tool. Your answers help estimate whether you might qualify, but only the research team can confirm your eligibility. This is not medical advice.
Question 1 of 70%